Alvine Pharmaceuticals raises $26 million for disease research
San Carlos, Calif. company Alvine Pharmaceuticals recently added $5 million to its first venture round, bringing total funding to $26 million, according to VentureWire.
Alvine’s research focuses on treatment for autoimmune and gastrointestinal diseases, and it started clinical trials in February for its treatment of celiac sprue, a condition that stems from the inability to process gluten. Backers include Cargill Ventures, Flagship Ventures, InterWest Partners, Prospect Venture Partners and Sofinnova Ventures.
Next Story: Roundup: Broadcom backdating, games at work, and more
Previous Story: Google Map Maker, map maker, make me a map (of the 3rd world)
About the Author, Anthony Ha
Anthony is VentureBeat's assistant editor, as well as its reporter on enterprise technology, cloud computing, and tech policy. Before joining VentureBeat in 2008, Anthony worked at the Hollister Free Lance, where he won awards from the California Newspaper Publishers Association for breaking news coverage and writing. He attended Stanford University and now lives in San Francisco. Reach him at anthony@venturebeat.com. You can also follow Anthony on Twitter.